The healthcare system in the United States is facing a crisis, with high costs and middling quality. The culprit? Big Medicine, a term that encompasses powerful middlemen in the healthcare industry, including pharmacy benefit managers (PBMs), insurance conglomerates, and wholesale drug distributors. These entities wield significant control over drug prices, insurance coverage, and the overall cost of healthcare, often at the expense of patients and independent providers.
One of the key players in this crisis are PBMs, who act as intermediaries between insurers, drug manufacturers, and pharmacies. While their stated purpose is to reduce drug costs, they often do the opposite. PBMs frequently steer patients toward pricier drugs, charge steep markups, and extract hidden fees, leading to higher costs for consumers. The situation is further exacerbated by the fact that the three largest PBMs are vertically integrated with major insurance conglomerates and pharmacies, creating a web of conflicts of interest.
The issue extends beyond PBMs to other Big Medicine entities. Drug wholesalers, such as McKesson, Cencora, and Cardinal Health, control a significant portion of the U.S. drug distribution market and are also vertically integrated with medical providers. This arrangement can lead to kickbacks and conflicts, where profit margins dictate treatment decisions, potentially overriding doctors' clinical judgment.
The pharmaceutical industry, or Big Pharma, is not without fault either. They abuse patents to maintain high drug costs and block competition from affordable generics. However, this doesn't absolve Big Medicine of its responsibilities. The industry's practices have led to a situation where Americans face the highest medical costs in the world, despite receiving only middling healthcare.
To address this crisis, policymakers have proposed aggressive legislation. The Break Up Big Medicine Act, introduced by Senators Elizabeth Warren and Josh Hawley, aims to break up the six largest Big Medicine companies, including PBMs, insurers, and wholesalers. This act would promote competition and lower healthcare costs by preventing these entities from owning or controlling healthcare providers.
Public support for such legislation is growing. A Morning Consult poll revealed that a majority of voters believe health insurance companies have too much control over medical decisions and drive up costs. Business leaders, like Mark Cuban, have endorsed breaking up these powerful entities. The American Economic Liberties Project, along with a coalition of 25 organizations, supports the Break Up Big Medicine Act, recognizing the systemic risks posed by the concentration of economic power in the healthcare sector.
The comparison to the Glass-Steagall Act during the Great Depression is apt. Just as the separation of commercial and investment banks was necessary to prevent systemic risks, breaking up Big Medicine may be crucial to safeguarding the U.S. healthcare system. While it may not solve all the system's problems, it could be a significant step towards a more equitable and affordable healthcare future.
